Circadian modulation by time-restricted feeding restores brain transcription and slows amyloid deposition in a mouse model of Alzheimer's disease.
Whittaker, D. S.; Akhmetova, L.; Romero, H.; Welsh, D. K.; Colwell, C. S.; Desplats, P.
Show abstract
Alzheimers disease (AD) is a tragic neurodegenerative disease affecting more than 5 million Americans. Circadian disruptions impact nearly all AD patients, with reversal of sleep/wake cycles and agitation in the evening being common disturbances that manifest early in disease. These alterations support a role for circadian dysfunction as a driver of AD, emphasizing a critical need to investigate the therapeutic potential of circadian-modulating interventions. One of the most powerful regulators of the circadian system is the daily feed/fast cycle. Here we show that time-restricted feeding (TRF) without caloric restriction, improved key disease components including behavior, disease pathology and transcription in the APP23 mouse model of Alzheimers disease. We found that TRF had the remarkable capability of simultaneously reducing amyloid deposition, increasing A{beta}42 clearance, improving sleep and hyperactivity, and normalizing transcription of circadian, AD and neuroinflammation-associated genes in APP23 mice. Thus, our study unveils for the first time that circadian modulation through timed feeding has far-reaching effects beyond metabolism and affects the brain as the substrate for neurodegeneration. Since the pleiotropic effects of TRF can substantially modify disease trajectory, this intervention has immediate translational value, addressing the crucial need for accessible approaches to reduce or halt AD progression.
Matching journals
The top 8 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- A Trem2*R47H mouse model without cryptic splicing drives age- and disease-dependent tissue damage and synaptic loss in response to plaques 95%
- APOE Christchurch enhances a disease-associated microglial response to plaque but suppresses response to tau pathology 94%
- Diabetic phenotype in mouse and humans with β-amyloid pathology reduces the number of microglia around β-amyloid plaques 94%
Similar papers in this journal
- Novel brain-penetrant inhibitor of G9a methylase blocks Alzheimer’s disease proteopathology for precision medication 96%
- Opposing roles of physiological and pathological amyloid-β on synapses in live human brain slice cultures 95%
- Identification of Chlamydia pneumoniae and NLRP3 inflammasome activation in Alzheimer's disease retina 95%
Similar papers in this journal
- Tau pathology in the dorsal raphe may be a prodromal indicator of Alzheimer's disease 95%
- Astrocyte biomarker signatures of amyloid-β and tau pathologies in Alzheimer’s disease 94%
- Genome-wide consensus transcriptional signatures identify synaptic pruning linking Alzheimer's disease and epilepsy 94%
Similar papers in this journal
- Regional interneuron transcriptional changes reveal pathologic markers of disease progression in a mouse model of Alzheimer's disease 95%
- Tunable Tau Expression in C. elegans Neurons Reveals that Early-AD Tau Phosphorylation Selectively Impacts Behavior and Mitochondrial Quality Control 95%
- Immune receptor LAG3 regulates microglia function duringAlzheimer's disease 95%